Navigation Links
AlphaRx Shareholder Update
Date:6/24/2009

MARKHAM, ON, June 24 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) releases letter to their shareholders:

Dear Shareholders,

We wanted to take a few minutes to update the current views on AlphaRx. For the first time in our corporate history, we ended our last quarter with a small profit. Aside from the fact that it was a small amount, it was significant on more than one front. The events that occurred over the past few weeks, have woke up investors around the world.

Our revenue is growing and our product pipeline remains robust and stronger than ever. We have 2 partnered products with potential milestone payments in excess of US$ 155 million which may generate a long-term stream of multi-million dollar royalty income. We at AlphaRx, have established research collaborations with leading specialty pharmaceutical companies and research institutions, such as the US Army. We have both benefited either financially or scientifically. Furthermore, these collaborations may lead to licensing agreements of our products.

We are in the forefront of nanomedicine development and we are poised to be the world's first pharmaceutical company to commercialize a polymeric-based nanomedicine for the treatment of nosocomial pneumonia.

Our goal, as it has been from Day number one, is to create profit for our shareholders and increase shareholder value. We believe we are succeeding. Thank you for your support. We will continue to keep you informed.

    Michael M. Lee

    President & CEO

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
2. AlphaRx Signs Cooperative Research and Development Agreement with US Army
3. AlphaRx Provides Corporate and Development Update
4. AlphaRxs Indaflex(TM) Continues its Clinical Development
5. AlphaRx CEO Accumulates More Company Shares
6. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
7. AlphaRx Announces Debt Conversion
8. AlphaRx To Present at 47th Annual ICAAC
9. All Seven Members of RBC Life Sciences Board of Directors Were Re-Elected During the Companys 2009 Annual Shareholders Meeting
10. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
11. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... (PRWEB) , ... April 30, 2017 , ... PracticeMatch, a ... increase in projected attendance for this year’s physician career fairs, with this year’s RSVPs ... complete schedule for the 2017 calendar year of national physician career fairs is located ...
(Date:4/29/2017)... S.C. (PRWEB) , ... April ... ... Southeast’s leading software and web development company, today announced the launch of ... DonorBridge is a solution combining decades of software innovation and industry expertise ...
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of dynamic transitions ... the next without having to set a single keyframe in Final Cut Pro ... video production. , TransDark features dynamic transitions that momentarily splits the RGB layers of ...
(Date:4/29/2017)... ... April 29, 2017 , ... Sterling Global Products ... fine retailers selling biodegradable, hanging flushable wipes dispensers and/or 42 count refill packs ... in San Antonio, Texas, operates more than 350 stores throughout Texas and expanding ...
(Date:4/29/2017)... ... April 29, 2017 , ... ... and recognize the positive impact veterinarians have on animal health and welfare as ... Organization for Animal Health (OIE) choose a theme each year and this year ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... Halo Labs announces the launch of a ... called the Horizon at PEGS 2017 in ... analyzes sub visible particulate matter in biopharmaceutical samples to ... early as candidate selection and pre-formulation. Halo ... organization Elion Labs for system validation. "We ...
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
Breaking Medicine Technology: